Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Predictive Model for Occurrence of Febrile Neutropenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Retrospective, Observational Study

Version 1 : Received: 1 November 2023 / Approved: 2 November 2023 / Online: 2 November 2023 (10:24:29 CET)

A peer-reviewed article of this Preprint also exists.

Morimoto, M.; Yokoya, Y.; Yoshida, K.; Kosako, H.; Hori, Y.; Mushino, T.; Tamura, S.; Ito, R.; Koyamada, R.; Yamashita, T.; Mori, S.; Mori, N.; Ohde, S. Predictive Model for Occurrence of Febrile Neutropenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Retrospective, Observational Study. Hematol. Rep. 2024, 16, 76-88. Morimoto, M.; Yokoya, Y.; Yoshida, K.; Kosako, H.; Hori, Y.; Mushino, T.; Tamura, S.; Ito, R.; Koyamada, R.; Yamashita, T.; Mori, S.; Mori, N.; Ohde, S. Predictive Model for Occurrence of Febrile Neutropenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Retrospective, Observational Study. Hematol. Rep. 2024, 16, 76-88.

Abstract

Febrile neutropenia (FN) is a major concern in patients undergoing chemotherapy for diffuse large B-cell lymphoma (DLBCL); however, the overall risk of FN is difficult to assess. This study aimed to develop a model for predicting the occurrence of FN in patients with DLBCL. In this multicenter, retrospective, observational analysis, a multivariate logistic regression model was used to analyze the association between FN incidence and pretreatment clinical factors. We included adult inpatients and outpatients (aged ≥ 18 years) diagnosed with DLBCL who were treated with chemotherapy. The study examined 246 patients. Considering FN occurring during the first cycle of chemotherapy as the primary outcome, a predictive model with a total score of 5 points was constructed as follows: 1 point each for viral hepatitis, extranodal involvement, and a high level of soluble interleukin-2 receptor and 2 points for lymphopenia. The area under the receiver operating characteristic curve of this model was 0.844 (95% confidence interval: 0.777–0.911). Our predictive model can assess the risk of FN before patients with DLBCL start chemotherapy, leading to better outcomes.

Keywords

febrile neutropenia; chemotherapy; diffuse large B-cell lymphoma; outcomes; multivariate logistic regression model

Subject

Medicine and Pharmacology, Hematology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.